Mostrando 7 resultados de: 7
Filtros aplicados
Publisher
Molecular Neurobiology(2)
Cells(1)
Current Pharmaceutical Design(1)
Expert Opinion on Drug Discovery(1)
Frontiers in Aging Neuroscience(1)
Área temáticas
Enfermedades(4)
Fisiología humana(3)
Farmacología y terapéutica(2)
Medicina y salud(2)
Sistemas fisiológicos específicos de los animales(1)
Área de conocimiento
Neurología(3)
Medicamento(2)
Medicina interna(2)
Neuropsicología(2)
Biología del desarrollo(1)
Origen
scopus(7)
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusA chronological review of potential disease-modifying therapeutic strategies for Alzheimer's disease
ReviewAbstract: Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that has become a worldwide hePalabras claves:Alzheimer’s disease, calcium, ER stress, glutamate, Neurodegeneration, neuroinflammation, Oxidative Stress, Parkinson’s DiseaseAutores:Antoni Camins, Auladell C., Busquets O., Espinosa-Jimenez T., Ettcheto M., Verdaguer E.Fuentes:scopusCorrection to: Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease (Molecular Neurobiology, (2018), 55, 9, (7327-7339), 10.1007/s12035-018-0868-4)
OtherAbstract: The original version of this article unfortunately contained mistake. The authors found that Fig. 4.Palabras claves:Autores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carrera M.V., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusEpigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
ArticleAbstract: Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated fPalabras claves:APPswe/PS1dE9 mice, Cognitive deficits, Epigallocatechin-3-gallate, hippocampus, obesity, unfolded protein responseAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopusInvolvement of JNK1 in Neuronal Polarization During Brain Development
ReviewAbstract: The c-Jun N-terminal Kinases (JNKs) are a group of regulatory elements responsible for the control oPalabras claves:asymmetric division, DCX, JNK1, MAP1B, MIGRATION, NMDAR, SCG10, synaptogenesis, WDR62Autores:Antoni Camins, Auladell C., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., Olloquequi J., Parcerisas A., Verdaguer E., Zárate C.B.Fuentes:scopusRole of c-jun N-terminal kinases (JNKs) in epilepsy and metabolic cognitive impairment
ReviewAbstract: Previous studies have reported that the regulatory function of the different c-Jun N-terminal kinasePalabras claves:BRAIN, C-Jun-N-terminal kinase, cognitive impairment, Epilepsy, JNK inhibitor, metabolism, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Espinosa-Jimenez T., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopus